Lisocabtagene Maraleucel

Introduction Overview

Generic Name

lisocabtagene maraleucel

Brand Name

Breyanzi

Dosage Form

suspension for intravenous infusion

Drug Class

Miscellaneous antineoplastics

Pharmacokinetics

Absorption

Breyanzi is administered as a suspension for intravenous infusion directly into the bloodstream, bypassing the gastrointestinal tract and systemic absorption barriers that characterize oral drug administration. As such, traditional absorption processes do not apply; the modified autologous T cells enter circulation immediately post-infusion, allowing for rapid systemic exposure and tissue distribution. Pre-infusion lymphodepleting chemotherapy prepares the patient’s system to enhance the proliferation and activity of the infused CAR T cells.

Distribution

After intravenous administration, lisocabtagene maraleucel (Breyanzi) CAR T cells distribute throughout the bloodstream and lymphoid tissues. These engineered T cells are capable of migrating to tumor sites, including lymph nodes and extranodal sites involved in lymphoma. Distribution is governed by their ability to traffic via vascular and lymphatic routes and home to specific tissue niches where malignant B cells reside. The expansion and persistence of CAR T cells in the body follow infusion and are integral to sustained antitumor activity; these parameters are influenced by factors such as preconditioning, patient immune status, and tumor burden.

Metabolism

Being a cellular therapy, Breyanzi is not metabolized by conventional enzymatic pathways like small-molecule drugs. Instead, the persistence and activity of the modified T cells are modulated by immune regulatory mechanisms and cellular turnover. The infused CAR T cells can expand upon antigen encounter and are eventually cleared through natural T-cell apoptosis and immune modulation. Cellular immunophenotype and exhaustion markers influence the longevity and metabolic profile of the CAR T cells after infusion.

Elimination

Elimination of Breyanzi involves the natural attrition and clearance of infused CAR T cells through immune-mediated cell death, apoptosis, and lack of antigen stimulation. The lifespan of these cells can range from weeks to months and is patient-specific. Clearance is not through renal or hepatic pathways but rather through immune homeostasis and cell senescence. Monitoring persistence of CAR T cells in peripheral blood is used as a surrogate for therapeutic durability.

Dosage Forms

Adults

Breyanzi is administered as a suspension for intravenous infusion. The therapy is delivered as a one-time dose via two infusions over a total period of up to 30 minutes. Prior to the infusion, patients typically receive lymphodepleting chemotherapy (e.g., fludarabine and cyclophosphamide) three days before the infusion to enhance CAR T cell engraftment. The dose of Breyanzi is personalized, calibrated based on patient parameters and the manufacturing yield of CAR T cells. Treatment requires administration in a specialized center experienced with CAR T cell therapies, with close monitoring for adverse effects post-infusion.

Adolescents

Currently, Breyanzi is FDA-approved primarily for adult patients with relapsed or refractory large B-cell lymphoma and related indications. It is not widely indicated in pediatric or adolescent populations; thus, dosing recommendations and administration guidelines for adolescents are limited. Use in these populations should be under strict clinical protocols and expert consultation.

Special Populations

Due to the nature of CAR T cell therapy, special populations such as patients with significant hepatic or renal impairment are generally not contraindicated, as pharmacokinetics are not dependent on drug metabolism or excretion. However, patients with active infections, immunodeficiency, or uncontrolled comorbidities may not be candidates. Geriatric patients are eligible, with dosing tailored as per individual health status. Due to complex manufacturing and personalized administration, special considerations apply to logistics and timing in all populations. Pregnant or breastfeeding women are advised against using Breyanzi, and contraception is recommended around treatment.

Mechanism Of Action

Breyanzi (lisocabtagene maraleucel) is a chimeric antigen receptor (CAR) T cell therapy which harnesses a patient's own genetically modified T cells to target and eliminate malignant B cells expressing the CD19 antigen. The therapeutic process begins with leukapheresis to collect T cells from the patient, which are then genetically engineered ex vivo to express a CAR that combines an antigen-recognition domain specific for CD19, a transmembrane domain, and intracellular signaling domains that activate the T cells upon antigen engagement.

Upon infusion back into the patient, these CAR T cells recognize CD19-expressing lymphoma cells via the engineered receptor, leading to CAR-mediated activation, proliferation, and release of cytotoxic mediators such as perforin and granzymes that induce apoptosis in the target malignant cells. This mechanism provides a highly specific and potent immune-mediated eradication of B cell malignancies. Additionally, the CAR T cells exhibit in vivo expansion and long-term persistence, contributing to sustained antitumor surveillance and remission.

Beyond direct cytotoxicity, Breyanzi’s CAR T cells orchestrate an endogenous immune response, potentially recruiting other immune effector cells and modulating the tumor microenvironment. Compared to traditional antibody therapies or chemotherapy, CAR T cell therapy provides a living drug capable of dynamic adaptation and prolonged activity. Clinical studies demonstrate that the dual signaling domains in the CAR construct optimize T cell activation and reduce exhaustion, improving therapeutic efficacy and safety profiles relative to earlier generation CAR T therapies.

Pharmacological Actions

Targeted cytotoxicity against CD19-expressing B-cell malignancies
In vivo proliferation and persistence of genetically engineered CAR T cells
Activation of immune effector mechanisms leading to apoptosis of cancer cells
Modification of tumor microenvironment through immune modulation
Induction of sustained antitumor immune response
Selective targeting minimizing off-target cytotoxicity
Bridging innate and adaptive immunity via antigen-specific activation
Ability to eliminate relapsed or refractory lymphoma cells resistant to conventional therapies

Therapeutic Clinical Uses

Treatment of relapsed or refractory large B-cell lymphoma including diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B in adults
Management of relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) after at least two prior therapies including BTK and BCL-2 inhibitors
Treatment of relapsed or refractory follicular lymphoma (FL) in adults after two or more prior systemic therapies
Therapy for adult patients with relapsed or refractory mantle cell lymphoma (MCL) post at least two prior lines of systemic treatment including a BTK inhibitor
Therapeutic option for patients ineligible for hematopoietic stem cell transplantation due to medical or age-related factors
Treatment of patients with lymphoma refractory to multiple prior regimens
Bridging therapy for patients with limited options after conventional chemotherapy failure
Potential to induce durable complete remission in select B-cell malignancies

Side Or Adverse Effects

Cytokine release syndrome (CRS) presenting as fever, chills, hypotension, hypoxia and multi-organ effects
Neurological toxicities including confusion, speech impairment, seizures, tremors, and encephalopathy
Infusion-related reactions such as fever, chills, and rigors
Common side effects including headache, dizziness, nausea, vomiting, diarrhea, constipation
Cardiac events manifesting as tachycardia or arrhythmias
Respiratory symptoms including cough and dyspnea
Musculoskeletal pain including bone, joint, and muscle discomfort
Increased risk of infections due to immunosuppression and neutropenia
Swelling and localized edema
Hematological toxicities including cytopenias such as anemia, thrombocytopenia, and neutropenia
Fatigue and general malaise post-infusion
Potential development of secondary malignancies post-treatment
Allergic reactions including urticaria and facial swelling
Gastrointestinal disturbances such as abdominal pain and diarrhea

Precautions

Administer only at specialized centers with appropriate expertise in CAR T cell therapies and supportive care
Monitor closely for signs of cytokine release syndrome and manage promptly with targeted interventions
Regular neurological assessments to detect early signs of neurotoxicity
Avoid live vaccinations 6 weeks before and after therapy due to immunosuppression
Advise patients to remain near the treatment center for at least 4 weeks post-infusion for monitoring
Use caution in patients with history of seizures, stroke, or CNS disorders
Screen for active infections including hepatitis B and C prior to treatment initiation
Evaluate pregnancy status and avoid use during pregnancy and breastfeeding
Careful selection of patients who have failed prior therapies and meet criteria for CAR T therapy
Prepare patients for lymphodepleting chemotherapy prior to infusion
Monitor organ function regularly including liver and renal panels
Educate patient on potential delayed adverse effects and need for ongoing surveillance
Ensure readiness to manage severe adverse events including ICU-level care

Warnings

Serious and potentially fatal cytokine release syndrome can occur, requiring immediate medical intervention
Life-threatening or severe neurological events including seizures, encephalopathy, and cerebral edema have been reported
Use contraindicated in patients with active infection or uncontrolled comorbid conditions
Potential increased risk of developing secondary malignancies after therapy
Avoid administering Breyanzi if dose or schedule is delayed due to logistical issues, as delayed infusion may impact efficacy
Risk of profound and prolonged cytopenias leading to severe infections or bleeding
Do not use in primary central nervous system lymphoma due to lack of efficacy data
Risk of tumor lysis syndrome in high tumor burden patients
Hypersensitivity reactions including anaphylaxis possible during or after infusion
Avoid driving or operating machinery for at least 2 weeks post-treatment due to neurological adverse effects
Pregnancy and breastfeeding contraindicated due to unknown fetal risks and immunosuppression
Careful monitoring required for cardiac events including arrhythmias

Contraindications

Known hypersensitivity to lisocabtagene maraleucel or components of the formulation
Active, uncontrolled infection at the time of planned infusion
Pregnancy and breastfeeding status without adequate contraception
Patients with primary central nervous system lymphoma (not indicated)
Incomplete recovery from prior lymphodepleting chemotherapy or immunosuppressive therapy
Concurrent administration of other investigational therapies
Patients lacking adequate organ function or performance status to tolerate therapy
Unwillingness or inability to comply with monitoring and follow-up requirements
Prior hematopoietic stem cell transplantation complications that contraindicate further cellular therapies
Known severe neurological disorders that may confound assessment or increase risk

Drug Interactions

No significant pharmacokinetic drug interactions due to cellular nature of therapy
Potential interactions with immunosuppressive agents used for lymphodepleting chemotherapy
Concurrent use of corticosteroids may reduce efficacy by suppressing T cell function
Avoid live vaccines during treatment and until immune recovery
Potential impact of concomitant infection management drugs on immune system activity
No noted interactions with commonly used antibiotics or antivirals, but monitor patient status
Interactions with other antineoplastic agents during preconditioning chemotherapy
Medications that may exacerbate neurologic adverse events need caution
Use with agents affecting cardiac function requires monitoring
Avoid use with drugs that could exacerbate cytokine release syndrome symptoms

Preparations Of The Drug

Breyanzi is supplied as a suspension for intravenous infusion in a sterile single-use vial
The suspension contains genetically modified autologous T cells expressing the anti-CD19 CAR
Manufacturing is personalized per patient following leukapheresis collection
Provided in vial formulations suitable for infusion after thawing and preparation under aseptic conditions
Available only through limited distribution programs in certified treatment centers
Accompanying lymphodepleting chemotherapy agents are provided separately and administered prior to Breyanzi infusion
Supplied with detailed prescribing and administration guidelines in the package insert
Not available in standard oral or parenteral forms other than intravenous cellular suspension